One-in-Five Intake Screen: ADHD Detection Pathway for Addiction and Outpatient Psychiatry
A standardized two-phase ADHD screening kit built into the intake process of addiction treatment centers and outpatient mental-health clinics, so the roughly one-in-five addiction patients and one-in-seven psychiatry outpatients with ADHD are found at the door instead of missed.
Concept
A standardized, two-phase ADHD detection kit embedded in the intake workflow of services that treat adults for other conditions: addiction treatment centers and general outpatient mental-health clinics. Phase 1: every new intake completes a brief, validated adult ADHD screen scored inside the existing workflow. Phase 2: screen-positives get a structured diagnostic assessment slot within the same service — not a referral into a separate, months-long ADHD waiting list — plus a treatment plan that accounts for how ADHD interacts with the primary condition (e.g., timing of stimulant initiation in active substance use). The kit fixes the instrument, the diagnostic criteria, and the follow-up pathway so results are comparable across sites, directly addressing the methodological variability that currently makes prevalence estimates unreliable. The single wedge: stop missing the hidden ADHD in services that are not ADHD services.
Why now
Paper [3] meta-analyzed 31 studies (12,524 participants) and estimated pooled ADHD prevalence at 21% among SUD patients — 25% in alcohol, 19% in cocaine, and 18% in opioid subpopulations — with ADHD associated with earlier onset and more severe SUD prognosis, so detection changes outcomes rather than just labels. Paper [5] found 14.61% pooled ADHD prevalence (CI 10.39–19.41) among adults attending outpatient psychiatric clinics, and showed that the screening scale used and the criteria applied (DSM-5 raises rates) materially change estimates — the exact problem a standardized two-phase protocol solves. Older corpus evidence [11] confirms substance use disorders are substantially elevated in adults with ADHD, so the comorbidity runs in both directions and each service is the other's highest-yield screening site.
Written by GLM · 14 Oct 2026
AI assessment
A high-utility clinical workflow tool that leverages strong meta-analytic evidence to capture a significant, underserved comorbid population in high-yield settings.
- Evidence strength 5/5
- The idea is directly supported by multiple meta-analyses (Papers 1, 2, and 3) showing high pooled prevalence rates (14-21%) and explicitly calling for the two-phase design proposed.
- Market pull 4/5
- Addiction centers and psychiatric clinics have a strong incentive to improve patient outcomes, as untreated ADHD is linked to more severe SUD prognosis.
- Novelty & moat 3/5
- While similar to the 'Teen Depression' idea, it applies a different clinical mechanism (SUD comorbidity) to a distinct adult population, though it remains a screening-and-referral pattern.
- Feasibility 5/5
- The MVP is a low-complexity software integration of validated scales and a scheduling trigger, requiring no new medical discovery.
- Wedge clarity 5/5
- The wedge is exceptionally sharp: targeting the 'hidden' ADHD population specifically within intake workflows of non-ADHD services.
- Simplicity / focus 5/5
- The product is a single, focused clinical pathway (Screen -> Assess -> Treat) without unnecessary platform bloat.
Scored by Gemma 4 · 14 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Hazelden Betty Ford Foundationorganization
One of the largest US addiction treatment providers; with ~21% pooled ADHD prevalence among SUD patients, a standardized intake screen addresses a known driver of early-onset, severe substance use in its patient population.
- LifeStance Healthcompany
A large US outpatient mental-health group; 14.61% pooled ADHD prevalence in outpatient psychiatry means roughly one in seven of its patients, and an intake screen fits its high-volume telehealth and in-person workflow.
- Priory Groupcompany
Runs both addiction treatment and psychiatric outpatient services in the UK, so the same two-phase kit covers both settings where the evidence shows elevated adult ADHD prevalence.
- American Society of Addiction Medicineorganization
Could standardize the two-phase protocol across member addiction programs, resolving the instrument and criteria variability that paper [5] documents and giving the field comparable data.
- National Institute on Drug Abuseorganization
A screening protocol deployed at scale across addiction programs would generate real-world data on treating ADHD in SUD populations, a priority research area given the 21% comorbidity estimate.
Research it builds on
- Anxiety, mood, and substance use disorders in adult men and women with and without attention-deficit/hyperactivity disorder: A substantive and methodological overviewCatharina Annette Hartman, Henrik Larsson, Melissa Vos et al. · 2023 · 99 citationsAll ideas from this paper →
- Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-AnalysisHenrik Rohner, Nikolas Gaspar, Alexandra Philipsen et al. · 2023 · 90 citationsAll ideas from this paper →
- ADHD in Adults: A Systematic Review and Meta-Analysis of Prevalence Studies in Outpatient Psychiatric ClinicsDimitrios Adamis, Caroline Flynn, Margo Wrigley et al. · 2022 · 42 citationsAll ideas from this paper →